<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02843334</url>
  </required_header>
  <id_info>
    <org_study_id>69HCL16_0271</org_study_id>
    <nct_id>NCT02843334</nct_id>
  </id_info>
  <brief_title>Study of the Prevalence of Fabry Disease in French Dialysis Patients</brief_title>
  <acronym>FABRYDIAL</acronym>
  <official_title>Study of the Prevalence of Fabry Disease in French Dialysis Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hospices Civils de Lyon</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hospices Civils de Lyon</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Fabry Disease (FD) is a rare genetic lysosomal storage disease including an X-linked mutation
      and characterized by an alpha-galactosidase A (GLA) deficiency. It causes
      globotriaosylceramide (GB3) accumulation within blood vessels, tissues and organs. This
      accumulation leads to multisystemic deficiency, such as progressive kidney insufficiency. Due
      to its low prevalence and non-specific symptoms, FD is under-diagnosed. Its estimated
      incidence is ranged from 1/40,000 to 1/120,000 live births. A review of the international
      literature suggests a higher prevalence among dialysis patients. Its diagnosis could lead to
      an enzyme replacement therapy, in order to avoid the occurrence or aggravation of other
      organs irreversible lesions, and to enhance the familial screening.

      We aim to conduct a multicentric cross-sectional prevalence study in 5 areas
      (Rhône-Alpes-Auvergne, Ile de France, Aquitaine, Picardie and department of Gard), involving
      biologic collection and genetic diagnosis test. Our objective is to measure the prevalence of
      FD among dialysis patients. Eligible patients will be included after signing the informed
      consent.

      In the five participating areas, all of the dialysis centers will be asked for involvement.
      Nominative data of the French renal epidemiology and information network (REIN) registry will
      enable first patients screening for eligibility among prevalent dialysis patients. If needed
      (insufficient or absent data in the REIN registry), data will be completed with medical
      files.

      A blood drop will be collected during a hemodialysis session (or the monthly test for
      peritoneal dialysis treated patients) and deposited on an anonymized blotting paper. For the
      diagnosis of FD, men will have a measure of the alpha-galactosidase activity, whereas
      screening in women will be established on the association of alpha-galactosidase activity and
      lyso-GB3 analysis. If results are compatible with FD, genetic mutation will be search in
      order to confirm the diagnosis for women, and, for all, to offer familial testing. Results
      will be transmitted to the nephrologist within the next 2 to 9 weeks. Patients diagnosed with
      FD will be managed in accordance with the guidelines of the French National Authority for
      Health (F.N.A.H.).
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>May 2016</start_date>
  <completion_date type="Anticipated">May 2017</completion_date>
  <primary_completion_date type="Anticipated">May 2017</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Cross-Sectional</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Prevalence of Fabry disease</measure>
    <time_frame>during a hemodialysis session (Day 1)</time_frame>
    <description>Analysis for the diagnostic of FD will be performed on blood drops:
For men : alpha galactosidase A enzyme activity (positive test if &lt; 1,2µmol/L/h)
For women : alpha galactosidase A enzyme activity (positive test if &lt; 1,2µmol/L/h) and lyso-GB3 (positive test if &gt; 6 ng/mL) analysis. If results are compatible, GLA mutation will be confirmed by genotyping.</description>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">6000</enrollment>
  <condition>Fabry Disease</condition>
  <condition>End Stage Renal Disease</condition>
  <condition>Renal Dialysis</condition>
  <arm_group>
    <arm_group_label>Population of adult patients undergoing chronic renal dialysis</arm_group_label>
    <description>Population of adult patients undergoing chronic renal dialysis for end stage kidney disease in 5 French areas (Rhône-Alpes-Auvergne, Ile de France, Aquitaine, Picardie and department of Gard)</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Dried blood spot (DBS) sampling</intervention_name>
    <description>DBS be collected during a hemodialysis session and deposited on an anonymized blotting paper. Laboratory ARCHIMED Life Science GmbH, based in Austria will perform all the biological analysis. For the diagnosis, men will have a measure of the alpha-galactosidase activity level, whereas screening in women will be established on the association of alpha-galactosidase activity and lyso-GB3 analyses. If results are compatible, genetic mutation will be searches in order to confirm the diagnosis for women.</description>
    <arm_group_label>Population of adult patients undergoing chronic renal dialysis</arm_group_label>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      blood drops will be collected during a hemodialysis session and deposited on an anonymized
      blotting paper. Mutational analysis with sequencing of the whole GLA gene will be done to
      confirm the diagnosis of Fabry disease
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Population of adult patients undergoing chronic renal dialysis for end stage kidney disease
        in 5 French areas (Rhône-Alpes-Auvergne, Ile de France, Aquitaine, Picardie and department
        of Gard)
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Woman or men

          -  Age between 18 to 70 years

          -  Patient undergoing chronic renal dialysis with a confirmed diagnosis of FD or a
             diagnosis of nephropathy according to the French renal epidemiology and information
             network (REIN) registry classification :

          -  Primitive glomerulonephritis

          -  Hypertension

          -  Diabetic nephropathy with non type 1 diabetes

          -  Vascular nephropathy

          -  Pyelonephritis

          -  Unknown or other

          -  Informed consent signed

        Exclusion Criteria:

          -  IgA nephropathy confirmed by renal biopsy

          -  Diabetic nephropathy with type 1 diabetes

          -  Autosomal dominant polycystic kidney disease

          -  Law-protected patient

          -  Patient who doesn't belong to the national social security system, or similar system

          -  Pregnant or lactating woman
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Laurent JUILLARD, Pr</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospices Civils de Lyon</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Laurent JUILLARD, Pr</last_name>
    <phone>(0)472 110 159</phone>
    <phone_ext>+33</phone_ext>
    <email>Laurent.juillard@univ-lyon1.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Florence SENS, MD</last_name>
    <phone>(0)472 115 769</phone>
    <phone_ext>+33</phone_ext>
    <email>Florence.sens@chu-lyon.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Hôpital Pellegrin Tripode, Service de néphrologie-Dialyse, place Amélie Rabat Léon</name>
      <address>
        <city>Bordeaux</city>
        <state>Aquitaine</state>
        <zip>33000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Valérie De PRECIGOUT, MD</last_name>
      <phone>(0)556 795 831</phone>
      <phone_ext>+33</phone_ext>
      <email>valerie.deprecigout@chu-bordeaux.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hôpital Universitaire Carémeau, Service de Néphrologie, Place du Pr R. Debré</name>
      <address>
        <city>Nîmes</city>
        <state>Gard</state>
        <zip>30029</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Olivier MORANNE, Pr</last_name>
      <phone>(0)466 683 256</phone>
      <phone_ext>+33</phone_ext>
      <email>olivier.moranne@chu-nimes.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hôpital Necker, APHP Paris, Service de néphrologie-dialyse, 149 rue de Sèvres</name>
      <address>
        <city>Paris</city>
        <state>Ile de France</state>
        <zip>75015</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bertrand KNEBELMANN, Pr</last_name>
      <phone>(0)144 495 241</phone>
      <phone_ext>+33</phone_ext>
      <email>bertrand.knebelmann@nck.aphp.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU d'Amiens, Site Sud, Service de néphrologie, D408</name>
      <address>
        <city>Amiens</city>
        <state>Nord Picardie</state>
        <zip>80054</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gabriel CHOUKROUN, Pr</last_name>
      <phone>(0)322 455 860</phone>
      <phone_ext>+33</phone_ext>
      <email>choukroun.gabriel@chu-amiens.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospices Civils de Lyon, Hôpital E Herriot, Service de néphrologie, 5 place d'Arsonval</name>
      <address>
        <city>Lyon</city>
        <state>Rhones Alpes</state>
        <zip>69437</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Laurent JUILLARD, Pr</last_name>
      <phone>(0)472 110 159</phone>
      <phone_ext>+33</phone_ext>
      <email>Laurent.juillard@univ-lyon1.fr</email>
    </contact>
    <contact_backup>
      <last_name>Laure GUITTARD</last_name>
      <phone>(0)472 112 801</phone>
      <phone_ext>+33</phone_ext>
      <email>Laure.guittard@chu-lyon.fr</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>July 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 21, 2016</study_first_submitted>
  <study_first_submitted_qc>July 21, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 25, 2016</study_first_posted>
  <last_update_submitted>July 21, 2016</last_update_submitted>
  <last_update_submitted_qc>July 21, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 25, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Fabry disease</keyword>
  <keyword>End Stage Renal Disease</keyword>
  <keyword>chronic dialysis</keyword>
  <keyword>alpha galactosidase A</keyword>
  <keyword>Lyso-GB3</keyword>
  <keyword>GLA mutation</keyword>
  <keyword>Prevalence</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Kidney Diseases</mesh_term>
    <mesh_term>Kidney Failure, Chronic</mesh_term>
    <mesh_term>Fabry Disease</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

